By identifying specific genetic mutations or protein expressions in lung cancer cells, clinicians can prescribe treatments that are more likely to be effective for the individual patient, such as tyrosine kinase inhibitors for patients with EGFR mutations [75]. This evidence concerns the gene EGFR and lung cancer.